Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3490)	1/13/2023 7:27:41 PM
From: A.J. Mullen	Read Replies (1) \| Respond to of 3557

I was thinking it was an insurance fund that was out of money, but as you say, it's a charitable institution. Regeneron offers information on "independent charitable institutions" that can help with copay. I wonder if it funds them. If so, the regular exhaustion of funds would provide information on the elasticity of demand in those getting aid. Hopefully that's not deliberate. It would cause many protests if it were. They're expecting to report Phase 3 three results for Dupixent in COPD H1, and to submit Libtayo with chemo to the EC in the same period. They also plan to start a bunch of combination trials with Libtayo this year. Ashley